Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company’s shareholders.

Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/

Since December 2023, shares of Amicus’ common stock have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value.

The investigation seeks to determine whether Amicus and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to investors in connection with recent corporate actions.

Amicus shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or if necessary, by copying and pasting the link into your browser):

https://kaskelalaw.com/case/amicus-therapeutics/

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

This notice may constitute attorney advertising in certain jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219358821/en/